GW Pharmaceuticals filed an investigational new-drug application with the FDA to conduct a pivotal, late-stage trial of Sativex as a treatment for spasticity in multiple sclerosis patients. The trial, which is expected to begin next year, will be carried out by GW's partner Otsuka Pharmaceutical. The drug is also in late-stage clinical development as a treatment for cancer pain.

Related Summaries